Why the study?
A comprehensive analysis of short-term outcomes for transcatheter mitral valve replacement in degenerated mitral bioprostheses, failed annuloplasty rings, and severe mitral annular calcification has not been performed.
Does transcatheter mitral valve replacement using aortic transcatheter heart valves provide favorable 30-day outcomes in poor surgical candidates with degenerated mitral bioprostheses, failed surgical rings, or severe mitral annular calcification?
Population
Patients with degenerated mitral bioprostheses, failed surgical repairs with annuloplasty rings, or severe mitral annular calcification
Comparison
MViV vs MViR vs ViMAC
Design
Retrospective registry analysis
Follow-up
30 days
Authors
Loading...
Supports MViV preference in high-risk patients; hypothesis-generating and requires randomized confirmation before practice change.
Does transcatheter mitral valve replacement using aortic transcatheter heart valves provide favorable 30-day outcomes in poor surgical candidates with degenerated mitral bioprostheses, failed surgical rings, or severe mitral annular calcification?
Transcatheter mitral valve replacement using aortic transcatheter heart valves shows favorable 30-day outcomes and symptom improvement, with valve-in-valve procedures demonstrating superior results compared to valve-in-ring and valve-in-MAC.
Guerrero et al. (2020) studied this question.